Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation “pill scare”
Authors:
- Lothar A.J. HeinemannLHLothar A.J. Heinemann
- Jürgen C. DingerJDJürgen C. Dinger
- Anita AssmannAAAnita Assmann
- Thai Do MinhTMThai Do Minh
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Contraception
- Vol. 81 (5) , 401-407
Abstract
No abstract availableKeywords
Funding Information
- Bayer Schering
This publication has 16 references indexed in Scilit:
- The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observationContraception, 2007
- Safety of a New Oral Contraceptive Containing DrospirenoneDrug Safety, 2004
- Interpretations. The changing scene-an unnecessary pill crisisHuman Reproduction Update, 1999
- The differential risk of oral contraceptives: the impact of full exposure history*Human Reproduction, 1999
- Superficial Thrombophlebitis and Deep Vein ThrombosisArchives of internal medicine (1960), 1997
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBMJ, 1996
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- The androgenicity of progestinsThe American Journal of Medicine, 1995
- Trinational case–control study of oral contraceptives and healthPharmacoepidemiology and Drug Safety, 1993